At today’s Annual General Meeting of Actelion Ltd (SIX: ATLN) held in Basel Switzerland, shareholders voted on a number of resolutions put forward by the Company’s Board and a Requesting Shareholder.
The meeting was attended by 486 shareholders, representing 78'430'215 shares or 60.41 % of the total outstanding shares.
Shareholders approved the Business Report, consisting of the Annual Report, the Annual Statutory Accounts and the Consolidated Accounts for the year 2010.
A proposal by the Board to appropriate available earnings from capital contribution and distribute as a dividend in the amount of CHF 0.80 per registered share, was passed by shareholders.
A request for information from a shareholder was addressed by the Board of Directors and a further request for a special audit “Sonderprüfung” was rejected.
Shareholders granted discharge to all members of the Board of Directors and of the Senior Management.
A proposal by the Board to approve the continuation of a share repurchase program, of up to CHF 800 million, which commenced in November 2010, was passed by shareholders.
Shareholders voted on a number of resolutions to amend Actelion’s Articles of Association as follows:
* A proposal to introduce a consultative vote on the Compensation Report was approved. * A proposal regarding the implementation of the Book Entry Securities Act was approved. * A proposal to remove the maximum limit in number of Board Members was rejected. * A proposal to reduce the Term of Office for Board Members to one year was approved. * A proposal that Shareholders should elect the Chairman of the Board at the AGM was rejected.
Shareholders voted against a proposal from the Requesting Shareholder to remove five members of the current Board.
Actelion’s shareholders voted to re-elect Dr. Jean-Paul Clozel, Mr. Juhani Anttila, and Mr. Carl Feldbaum to the Board for a term of one year.
Shareholders also voted to elect two new Directors, Dr. Jean-Pierre Garnier and Mr. Robert Bertolini to the Board for a term of one year.
Following the AGM, Actelion’s Board comprises a total of eleven members: Robert E. Cawthorn (Chairman), Jean-Pierre Garnier (Vice-Chairman), Joseph C. Scodari (Vice-Chairman), Juhani Anttila, Robert Bertolini, Jean-Paul Clozel, Carl Feldbaum, Werner Henrich, Michael Jacobi, Armin Kessler, and Jean Malo.
Finally, shareholders confirmed Ernst & Young as the Company’s statutory auditors for the year 2011.
For further information please contact:
Roland Haefeli Vice President, Head of Investor Relations & Public Affairs Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil +41 61 565 62 62 +1 650 624 69 36 www.actelion.com: http://www.actelion.com/
